Recent Analysts’ Ratings Updates for Bright Minds Biosciences (DRUG)

Bright Minds Biosciences (NASDAQ: DRUG) has recently received a number of price target changes and ratings updates:

• 2/28/2026 – Bright Minds Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/17/2026 – Bright Minds Biosciences had its “buy” rating reaffirmed by BTIG Research. They now have a $147.00 price target on the stock.
• 2/14/2026 – Bright Minds Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/13/2026 – Bright Minds Biosciences was given a new $126.00 price target by Robert W. Baird.
• 1/10/2026 – Bright Minds Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 1/7/2026 – Bright Minds Biosciences was given a new $142.00 price target by Robert W. Baird.
• 1/6/2026 – Bright Minds Biosciences had its price target raised by BTIG Research from $72.00 to $147.00. They now have a “buy” rating on the stock.
• 1/2/2026 – Bright Minds Biosciences had its “buy” rating reaffirmed by Chardan Capital. They now have a $80.00 price target on the stock.

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.